CL2020000855A1 - Anticuerpos monoclonales anti-trkb y métodos de uso. - Google Patents

Anticuerpos monoclonales anti-trkb y métodos de uso.

Info

Publication number
CL2020000855A1
CL2020000855A1 CL2020000855A CL2020000855A CL2020000855A1 CL 2020000855 A1 CL2020000855 A1 CL 2020000855A1 CL 2020000855 A CL2020000855 A CL 2020000855A CL 2020000855 A CL2020000855 A CL 2020000855A CL 2020000855 A1 CL2020000855 A1 CL 2020000855A1
Authority
CL
Chile
Prior art keywords
antibodies
methods
trkb
agonist
monoclonal anti
Prior art date
Application number
CL2020000855A
Other languages
English (en)
Spanish (es)
Inventor
Susan D Croll
Min Gao
Ying Hu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2020000855A1 publication Critical patent/CL2020000855A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2020000855A 2017-11-30 2020-03-31 Anticuerpos monoclonales anti-trkb y métodos de uso. CL2020000855A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762592657P 2017-11-30 2017-11-30

Publications (1)

Publication Number Publication Date
CL2020000855A1 true CL2020000855A1 (es) 2020-07-31

Family

ID=64665125

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2020000855A CL2020000855A1 (es) 2017-11-30 2020-03-31 Anticuerpos monoclonales anti-trkb y métodos de uso.
CL2024002612A CL2024002612A1 (es) 2017-11-30 2024-08-30 Anticuerpo anti-receptor tropomiosina quinasa b (trkb); composición farmacéutica; y su uso.
CL2024002614A CL2024002614A1 (es) 2017-11-30 2024-08-30 Anticuerpo anti-receptor tropomiosina quinasa b (trkb); composición farmacéutica; y su uso.

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2024002612A CL2024002612A1 (es) 2017-11-30 2024-08-30 Anticuerpo anti-receptor tropomiosina quinasa b (trkb); composición farmacéutica; y su uso.
CL2024002614A CL2024002614A1 (es) 2017-11-30 2024-08-30 Anticuerpo anti-receptor tropomiosina quinasa b (trkb); composición farmacéutica; y su uso.

Country Status (18)

Country Link
US (3) US11066474B2 (https=)
EP (1) EP3717514A1 (https=)
JP (2) JP7438937B2 (https=)
KR (1) KR20200090779A (https=)
CN (2) CN121181700A (https=)
AU (3) AU2018375340B2 (https=)
BR (1) BR112020006976A2 (https=)
CA (1) CA3083452A1 (https=)
CL (3) CL2020000855A1 (https=)
CO (1) CO2020004075A2 (https=)
EA (1) EA202090966A1 (https=)
IL (1) IL273538B2 (https=)
MA (1) MA51207A (https=)
MX (3) MX2020003550A (https=)
MY (1) MY203247A (https=)
PH (1) PH12020550409A1 (https=)
SG (1) SG11202002665UA (https=)
WO (1) WO2019108662A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
JP7361031B2 (ja) * 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
US11066474B2 (en) * 2017-11-30 2021-07-20 Regeneron Pharmaceuticals, Inc. Anti-TrkB monoclonal antibodies and methods of use
JP7524158B2 (ja) * 2019-03-04 2024-07-29 公益財団法人東京都医学総合研究所 Ｔｒｋ断片をコードする核酸構築物、及びその利用
US12559560B2 (en) * 2020-01-30 2026-02-24 Fred Hutchinson Cancer Center Antibody-based compositions for targeting tropomyosin receptor kinase B (TrkB) isoforms
WO2023125485A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkB ANTIBODY AND APPLICATION THEREOF
IL315955A (en) 2022-03-30 2024-11-01 Peptidream Inc Peptide complex having trkb binding activity
CN120665203B (zh) * 2025-06-18 2026-03-27 广东优赛生物医药科技有限公司 一种药物组合物及其在治疗中枢性肥胖中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6225282B1 (en) 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
GT200600240A (es) 2005-06-06 2007-03-14 Anticuerpos monoclonales anti-trkb y usos de los mismos
CN101400367A (zh) * 2006-02-02 2009-04-01 瑞纳神经科学公司 施用trkb激动剂治疗不希望的重量减轻或进食障碍的方法
JP2009525319A (ja) 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
EP2087007A2 (en) 2006-11-09 2009-08-12 Irm Llc Agonist trkb antibodies and uses thereof
WO2008078179A1 (en) 2006-12-20 2008-07-03 Rinat Neuroscience Corporation Trkb agonists for treating autoimmune disorders
WO2009048605A1 (en) 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
PE20091326A1 (es) 2008-01-17 2009-09-18 Irm Llc Anticuerpos anti-trkb mejorados
WO2010086828A2 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
WO2011103667A1 (en) 2010-02-26 2011-09-01 6452728 Canada Inc. Agonistic antibodies to trkb receptors and uses thereof
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
US10080745B2 (en) 2013-11-25 2018-09-25 The Regents Of The University Of California Santa Cruz Piericidin bacterial inhibitors
ES2936810T3 (es) 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
KR20180037994A (ko) 2015-07-28 2018-04-13 오토노미, 인코포레이티드 TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법
JP7039468B2 (ja) * 2015-11-17 2022-03-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 神経およびその他の障害の処置のための結合アゴニスト
EP3452088A4 (en) * 2016-05-03 2020-04-15 The Scripps Research Institute TRKB AGONIST ANTIBODIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
CN110753702B (zh) 2017-03-15 2022-09-20 清华大学 抗trkb抗体
US11066474B2 (en) * 2017-11-30 2021-07-20 Regeneron Pharmaceuticals, Inc. Anti-TrkB monoclonal antibodies and methods of use

Also Published As

Publication number Publication date
CL2024002612A1 (es) 2025-01-24
MX2025001445A (es) 2025-03-07
CN111372949A (zh) 2020-07-03
AU2026200583A1 (en) 2026-02-19
JP2024016204A (ja) 2024-02-06
US12037401B2 (en) 2024-07-16
CA3083452A1 (en) 2019-06-06
AU2026200616A1 (en) 2026-02-19
US20220411515A1 (en) 2022-12-29
MX2025001444A (es) 2025-03-07
MX2020003550A (es) 2020-08-03
EA202090966A1 (ru) 2020-08-26
MA51207A (fr) 2020-10-07
CN121181700A (zh) 2025-12-23
CO2020004075A2 (es) 2020-08-31
NZ763618A (en) 2025-05-02
IL273538B2 (en) 2024-10-01
US20240309100A1 (en) 2024-09-19
IL273538B1 (en) 2024-06-01
KR20200090779A (ko) 2020-07-29
IL273538A (en) 2020-05-31
BR112020006976A2 (pt) 2020-10-13
CL2024002614A1 (es) 2025-01-24
AU2018375340A1 (en) 2020-05-07
CN111372949B (zh) 2026-02-03
WO2019108662A1 (en) 2019-06-06
US20190161551A1 (en) 2019-05-30
JP7438937B2 (ja) 2024-02-27
US11066474B2 (en) 2021-07-20
JP2021507677A (ja) 2021-02-25
MY203247A (en) 2024-06-19
PH12020550409A1 (en) 2021-04-12
AU2018375340B2 (en) 2025-10-30
EP3717514A1 (en) 2020-10-07
SG11202002665UA (en) 2020-04-29

Similar Documents

Publication Publication Date Title
CL2020000855A1 (es) Anticuerpos monoclonales anti-trkb y métodos de uso.
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
CL2018000703A1 (es) Anticuerpos anti-pdgfr-beta y usos de los mismos (divisional de sol. n°1924-15)
CO2019012998A2 (es) Proteínas de unión a antígenos trem2 y usos de estas
ECSP18094857A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
MX374501B (es) Formulaciones de anticuerpos de her2 subcutáneas.
IL282624A (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MX2021003765A (es) Proteínas il-12 de fusión a fc heterodimérico.
DOP2019000191A (es) Anticuerpos anti-tgf-beta y su uso
MX2021003110A (es) Agonistas del receptor x farnesoide y usos de los mismos.
CL2020001797A1 (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas.
CL2018000101A1 (es) Anticuerpos dirigidos contra il-33 y sus usos (divisional de la solicitud 201502469)
CU24564B1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
MX381639B (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
CL2018001652A1 (es) Composiciones y métodos para disminuir la expresión de tau
GT201800018A (es) Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
CO2017000346A2 (es) Anticuerpos de unión a protofibrillas aβ
CO2022003156A2 (es) Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15rα y su uso
EA201791005A1 (ru) Улучшенные антитела против il-6
MX393900B (es) Uso de gaboxadol en el tratamiento de tinnitus.
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
CO6592047A2 (es) Formulación tópica oftálmica de péptidos
MX2018016003A (es) Tratamiento combinado para lesiones neurológicas.